Brilinta (ticagrelor)

pCPA File Number: 20954

Negotiation Status:

Concluded without agreement

Indication(s):

Prevention of atherothrombotic events with history of myocardial infarction

Sponsor/Manufacturer:

AstraZeneca Canada Inc.

CDA-AMC Project Number:

SR0474-000

pCPA Engagement Letter Issued:

2017-08-04

Negotiation Process Concluded:

2017-11-30